Algert Global LLC Trims Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Algert Global LLC reduced its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 66.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 179,485 shares of the company’s stock after selling 355,872 shares during the period. Algert Global LLC owned about 0.08% of Hims & Hers Health worth $3,624,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HIMS. Nisa Investment Advisors LLC boosted its position in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC boosted its position in shares of Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the period. Van ECK Associates Corp bought a new position in shares of Hims & Hers Health in the second quarter worth approximately $111,000. Belpointe Asset Management LLC boosted its position in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after purchasing an additional 1,205 shares during the period. Finally, Amalgamated Bank boosted its position in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HIMS has been the subject of a number of recent analyst reports. Jefferies Financial Group upped their price target on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. Bank of America dropped their price target on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, September 13th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Finally, Needham & Company LLC began coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.86.

Insider Activity

In other news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $20.75, for a total value of $3,919,426.00. Following the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $695,166.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $20.75, for a total value of $3,919,426.00. Following the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $695,166.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Michael Chi sold 2,054 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $22.00, for a total transaction of $45,188.00. Following the completion of the transaction, the insider now directly owns 185,326 shares in the company, valued at approximately $4,077,172. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 731,473 shares of company stock valued at $12,671,277. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Trading Up 3.7 %

Shares of HIMS opened at $18.43 on Tuesday. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $25.74. The company has a market cap of $3.96 billion, a P/E ratio of -1,842.50 and a beta of 1.05. The company’s fifty day simple moving average is $16.89 and its 200-day simple moving average is $17.22.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. During the same quarter in the prior year, the firm posted ($0.03) earnings per share. The business’s revenue for the quarter was up 51.8% on a year-over-year basis. Analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.